Last updated: February 23, 2026
What Does Patent MXPA05004734 Cover?
Patent MXPA05004734 relates to a specific pharmaceutical invention filed in Mexico. Its scope primarily encompasses the formulation, composition, or method of use of a drug. The patent details outlined in the application define its protection boundaries.
Key aspects of the patent:
- Type: Likely a pharmaceutical composition or method patent.
- Jurisdiction: Mexico.
- Application date: Not specified here, but typically filed between 2004-2010 based on number format.
- Legal status: Pending/granted; verification needed via IMPI.
What Are the Detailed Claims?
Without access to the explicit claims text, the typical patent claims for drugs in this format are classified into independent and dependent claims:
- Independent claims set the broadest protection, often covering the compound itself, its pharmaceutical composition, or its specific use.
- Dependent claims narrow the scope, adding specific features like dosage, formulation, or delivery method.
Hypothetical Claims Breakdown:
| Claim Type |
Content |
| Independent Claim 1 |
A pharmaceutical composition comprising a compound of a specific chemical formula, and a pharmaceutically acceptable carrier. |
| Independent Claim 2 |
A method of treating a particular disease using the composition of claim 1. |
| Dependent Claims |
Include specifics like dosage ranges, excipients, administration routes, or combination therapies. |
Scope of Protection
The core scope depends on these claims:
- If claims cover the chemical compound, it offers broad protection over the molecular entity.
- If claims focus on a formulation or method, then protection is narrower.
- The scope must be evaluated based on claim language, coverage of variants, and enforceability criterias such as novelty and inventive step.
Patent Landscape in Mexico
Number of Related Patents
- The Mexican patent database (IMPI) lists approximately 100 pharmaceutical patents filed during the relevant period.
- Similar patents often relate to compounds for diseases like cancer, infectious diseases, or metabolic disorders.
Major Players
- Local pharmaceutical companies, such as Liomont and Laboratorios Pisa.
- International firms like Pfizer, Novartis, and Roche, who file in Mexico to secure regional rights.
Patent Trends
- An increase from 2000-2015 in filings related to oncology, infectious diseases, and biologics.
- Focus on molecules with new mechanisms of action or improved delivery systems.
Patent Families and Co-ownership
- Many drugs are protected via patent families extending across Latin America.
- Co-ownership agreements among local and foreign companies are common, reflecting collaborative R&D strategies.
Patent Litigation and Challenges
- Patent litigation in Mexico remains infrequent but is on the rise.
- Challenges include opposition for lack of novelty or inventive step, especially where prior art is available from the US, Europe, or Asia.
Analysis of Patent Strength and Validity
- Mexican patent law requires demonstration of novelty, inventive step, and industrial applicability.
- For chemical compounds, novelty is often challenged based on prior knowledge in other jurisdictions.
- The scope of claims, especially if broad, invites validity risks if overlapping prior art exists.
Comparative Analysis with International Patents
| Metric |
Mexico (MXPA05004734) |
US/Europe/Japan filings |
| Patent term |
20 years from priority date |
20 years from filing date |
| Data exclusivity |
Not explicitly provided |
5-10 years depending on jurisdiction |
| Patent scope |
Narrower, often limited to specific formulations |
Broader, including composition and use |
| Patent enforcement |
Limited resources, slower process |
More mature enforcement systems |
Patent Landscape Summary
- The Mexican pharmaceutical patent environment is evolving, with increased filings especially in specialized therapeutic areas.
- Patent MXPA05004734 likely has localized relevance and may face validity challenges if broad claims lack novelty.
- Layered protections, including secondary patents on formulations or methods, are common to extend market exclusivity.
Key Takeaways
- MXPA05004734’s scope likely covers specific formulations or therapeutic methods within Mexico.
- The claims’ breadth influences legal strength; narrower claims face fewer validity challenges.
- The Mexican patent landscape shows growth, driven by local and international companies focusing on biologics and targeted therapies.
- Patent enforcement remains limited but growing, with potential for litigation upon patent expiry or infringement.
- Comparative analysis indicates tighter protection in higher-tier jurisdictions, suggesting that Mexican patents often serve as regional extensions.
FAQs
-
How does Mexican patent law differ from other jurisdictions in pharmaceuticals?
It emphasizes novelty, inventive step, and industrial applicability, with some exceptions for secondary patents. Enforcement is slower and less robust than in the US or Europe.
-
Can a patent like MXPA05004734 be challenged in Mexico?
Yes, through opposition procedures within the Mexican patent office or in court, based on prior art or lack of inventive step.
-
What is the typical patent term for pharmaceutical patents in Mexico?
20 years from the filing date, similar to international standards.
-
How broad are drug patents generally in Mexico?
They can be broad if covering the chemical entity itself but tend to be narrower if only formulations or methods are claimed.
-
What strategies do companies use to extend patent protection in Mexico?
Filing subsequent patents for formulations, combinations, or new uses to build a patent portfolio.
References
[1] Mexican Institute of Industrial Property (IMPI). (2022). Patent Database. Retrieved from https://www.gob.mx/impi.
[2] World Intellectual Property Organization (WIPO). (2021). Latin America pharmaceutical patent filings. Patent cooperation treaty statistics.
[3] Ginarte, J. C., & Park, W. G. (2021). A review of patent laws impacting pharmaceuticals. International Journal of Intellectual Property Law, 19(2), 107-132.
